Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals · CIK 0000200406
$267.61
+3.81% · delayed ~15 min
Last price from Oct 22, 2026
$644.30B market value
From JOHNSON & JOHNSON's FY2025 10-K, filed Feb 11, 2026 · read the filing
JOHNSON & JOHNSON develops and makes medicines. It took in $94.19B last year, which makes it a very large company. Of every dollar it sells, about 28 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 4 insiders, not under a pre-arranged plan.
$57.9M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From JOHNSON & JOHNSON's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$14.07B → $26.80B
Profit margin
15.8% → 28.5%
Earnings per share
$5.84 → $11.13
Long-term debt
$30.65B → $39.44B
Measured against FY2024, from the 10-K filed Feb 11, 2026
Improved: +90.6%
$14.07B to $26.80BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
JNJ rose 3.81% on the latest quote. The average Health Care company tracked here moved +1.56%, and the S&P 500 −1.04%. That is 2.2 points above its sector and 4.9 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 13% a year for the next 10 years. Over the last 12 years it grew by about 3% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 28 cents of every dollar of sales as profit, earning $26.80B last year.
Slowly. Sales grew 6.0% last year.
No. Its borrowings would take under a year of cash flow to clear. For every $1 it owes, it owns $1.69 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $26.80B and generated $24.53B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 11, 2026Filing for FY2025 | FY202410-K · Feb 13, 2025Filing for FY2024 | FY202310-K · Feb 16, 2024Filing for FY2023 | FY202210-K · Feb 16, 2024Filing for FY2022 | FY202110-K · Feb 17, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $94.19B | $88.82B | $85.16B | $78.74B | $82.58B | +6.0% |
| Cost of revenue | $30.26B | $27.47B | $26.55B | $23.40B | $28.43B | +10.1% |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.34B | $54.16B | +4.2% |
| Gross marginGross profit ÷ revenueWhat is this? | 67.9% | 69.1% | 68.8% | 70.3% | 65.6% | −1.2 pts |
| Selling, general and administrative | $23.68B | $22.87B | $21.51B | $20.12B | $22.08B | +3.5% |
| Interest expense | $971.0M | $755.0M | $772.0M | $183.0M | $201.0M | +28.6% |
| Income before tax | $32.58B | $16.69B | $15.06B | $19.18B | $16.50B | +95.2% |
| Net income | $26.80B | $14.07B | $35.15B | $20.88B | $14.71B | +90.6% |
| Net marginNet income ÷ revenueWhat is this? | 28.5% | 15.8% | 41.3% | 26.5% | 17.8% | +12.6 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $11.13 | $5.84 | $13.50 | $7.94 | $5.60 | +90.6% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| JNJJOHNSON & JOHNSON · this page | 9.0/10 | 4/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 11,070 shares at $131.94 ($1.5M)
Holds 36,517 shares after this filing.
Sold on the open market — 11,070 shares at $274.74 ($3.0M)
Holds 25,447 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q3 FY2026
Revenue +5.9% · Profit margin −20.6 pts · Profit -95.9% — against Q3 FY2025
Read the filingPublished results
Read the filingWrite down why you are following JOHNSON & JOHNSON, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 396 subsidiaries named in its 10-K, incorporated across 88 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from JNJ's 10-K for fiscal year 2025 (period ending 2025-12-28, filed Feb 11, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 4/9 | 10-K, filed Feb 11, 2026 |
| FY2024 | 9.0 | 5/9 | 10-K, filed Feb 13, 2025 |
| FY2023 | 8.0 | 6/9 | 10-K, filed Feb 16, 2024 |
| FY2022 | 9.0 | 9/9 | 10-K, filed Feb 17, 2022 |
| FY2021 | 10.0 | 3/3 | 10-K, filed Feb 22, 2021 |
| FY2019 | 9.0 | 5/9 | 10-K, filed Feb 18, 2020 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
4 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
5.51
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.26
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +12.6 pts
15.8% to 28.5%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +90.6%
$5.84 to $11.13Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +28.7%
$30.65B to $39.44BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -18.2%
$24.11B to $19.71BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +6.0%
$88.82B to $94.19BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: −1.2 pts
69.1% to 67.9%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Changed: +9.2%
$4.42B to $4.83BNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q3 FY2026 against Q3 FY2025, from the 10-Q filed Oct 21, 2026 — read it.
Deteriorated: -95.9%
$5.15B to $210.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −20.6 pts
21.5% to 0.8%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -95.9%
$2.14 to $0.09Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +5.9%
$23.99B to $25.40BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: −1.4 pts
69.6% to 68.1%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: -9.2%
$39.41B to $35.80BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Deteriorated: -7.2%
$18.23B to $16.91BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q3 FY2026 against Q2 FY2026, from the 10-Q filed Oct 21, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -96.2%
$5.53B to $210.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −21.0 pts
21.9% to 0.8%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -96.2%
$2.30 to $0.09Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -17.2%
$20.42B to $16.91BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 10% and 15%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 30 analysts covering this company, as of . Their views, not this site's.
Of 30 analysts publishing on this company, 7 say strong buy, 15 say buy and 8 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 0.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 39.9x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 6.0% |
| 28.5% |
| 24.04x |
| 1.44x |
| LLYELI LILLY & Co | 9.0/10 | 7/9 | 44.7% | 31.7% | 60.03x | 3.24x |
|---|
| MRKMerck & Co., Inc. | 9.0/10 | 5/9 | 1.3% | 28.1% | 20.38x | 1.60x |
|---|
| PFEPFIZER INC | 7.0/10 | 6/9 | -1.6% | 12.4% | 22.19x | 1.40x |
|---|
| BMYBRISTOL MYERS SQUIBB CO | 8.0/10 | 9/9 | -0.2% | 14.6% | 18.12x | 3.87x |
|---|
| ZTSZoetis Inc. | 9.0/10 | 7/9 | 2.3% | 28.2% | 13.04x | 3.64x |
|---|
| VTRSViatris Inc | 4.0/10 | 5/9 | -3.0% | -24.7% | — | 1.53x |
|---|
| Median of peers | 8.5/10 | — | 0.5% | 21.4% | 20.38x | 2.42x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Exercised stock options — 22,527 shares at $151.41 ($3.4M)
Holds 47,974 shares after this filing.
Sold on the open market — 22,527 shares at $274.74 ($6.2M)
Holds 25,447 shares after this filing.
Exercised stock options — 15,000 shares at $115.67 ($1.7M)
Holds 209,451 shares after this filing.
Sold on the open market — 15,000 shares at $263.36 ($4.0M)
Holds 194,451 shares after this filing.
Exercised stock options — 123,291 shares at $115.67 ($14.3M)
Holds 399,258 shares after this filing.
Sold on the open market — 20,976 shares at $262.00 ($5.5M)
Holds 378,282 shares after this filing.
Sold on the open market — 102,315 shares at $261.00 ($26.7M)
Holds 275,967 shares after this filing.
Sold on the open market — 41,957 shares at $258.06 ($10.8M)
Holds 282,490 shares after this filing.
Sold on the open market — 6,523 shares at $258.74 ($1.7M)
Holds 275,967 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 33,597 shares ($9.2M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 15,000 shares ($4.0M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 123,291 shares ($32.2M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 15,918 shares ($4.1M) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 48,480 shares ($12.4M) on or after .
Shares originally obtained via Executive compensation.
Filed notice to sell 23,054 shares ($5.8M) on or after .
Shares originally obtained via Stock Option Exercise.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Had a director or senior officer leave or join
Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2026
Revenue +6.6% · Profit margin −1.5 pts · Gross profit +7.1% — against Q2 FY2025
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +9.9% · Profit margin −28.5 pts · Profit -52.4% — against Q1 FY2025
Read the filingPublished results · Reported another event
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +6.0% · Profit margin +12.6 pts · Profit +90.6% — against FY2024
Read the filingPublished results
Read the filingQuarterly report for Q3 FY2025
Revenue +6.8% · Profit margin +9.5 pts · Profit +91.2% — against Q3 FY2024
Read the filingPublished results · Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2025
Revenue +5.8% · Profit margin +2.4 pts · Profit +18.2% — against Q2 FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingThe first 40 of 396. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-11. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Dow Jones Top Movers Today: PG and JNJ Lead Gainers, CAT and AMZN Lead Losers
ChartMill ·
Dow Jones Top Movers: Gainers and Losers on October 22, 2026
ChartMill ·
Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up
Yahoo ·
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
Yahoo ·
JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up
Yahoo ·
Kevin O’Leary’s Mother Kept the Same Portfolio for 55 Years and Outperformed Most Hedge Funds
Yahoo ·
Was There Any Sign Merck Stock Would Run?
Yahoo ·
Social Security Isn’t Enough: 5 Secure Dividend Stocks to Fund Your Retirement
Yahoo ·
Is Johnson & Johnson Stock Ready For A MedTech Stall?
Yahoo ·
Can Boston Scientific Stock Jump 30%?
Yahoo ·
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
Yahoo ·
How Has Intuitive Surgical's Story Changed?
Yahoo ·
Primary sources and further research